|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Biochemistry and Molecular
Biology, Monash University, Clayton, Victoria, Australia; the
Department of Medicine, Monash University, Box Hill, Victoria,
Australia; the Department of Biochemistry and Molecular Biology,
University of Georgia, Athens, GA; Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Springhouse, PA; and the
Departments of Microbiology and Immunology, Jagiellonian University,
Krakow, Poland.
The bacterium Porphyromonas gingivalis is a major
etiologic agent in the pathogenesis of adult periodontitis in humans.
Cysteine proteinases produced by this pathogen, termed gingipains, are considered to be important virulence factors. Among many other potentially deleterious activities, arginine-specific gingipains-R (RgpB and HRgpA) efficiently activate coagulation factors. To further
expand knowledge of the interaction between gingipains and the clotting
cascade, this study examined their effects on cellular components of
the coagulation system. The enzymes induced an increase in
intracellular calcium in human platelets at nanomolar concentrations
and caused platelet aggregation with efficiency comparable to thrombin.
Both effects were dependent on the proteolytic activity of the enzymes.
Based on desensitization studies carried out with thrombin and peptide
receptor agonists, and immunoinhibition experiments, gingipains-R
appeared to be activating the protease-activated receptors, (PAR)-1 and
-4, expressed on the surface of platelets. This was confirmed by the
finding that HRgpA and RgpB potently activated PAR-1 and PAR-4 in
transfected cells stably expressing these receptors. Cumulatively, the
results indicate the existence of a novel pathway of host cell
activation by bacterial proteinases through PAR cleavage. This
mechanism not only represents a new trait in bacterial pathogenicity,
but may also explain an emerging link between periodontitis and
cardiovascular disease.
(Blood. 2001;97:3790-3797) Proteolytic modification of intracellular and
extracellular proteins has recently been recognized as an important and
common mechanism of regulating cell function.1,2
Extracellularly, transformation of the cell surface through proteolysis
plays a role in cell migration, wound healing, and tissue
remodeling.3,4 In addition, a cohort of biologically
active compounds, including cytokines and cytokine receptors, growth
factors and growth factor receptors, cell surface adhesion molecules,
Fc receptors, and G protein-coupled receptors, are known to be
released from cell surfaces through proteolytic
cleavage.5,6 Under physiologic conditions, it has been
well established that enzymes belonging to a family of tightly
regulated metalloproteases, which contain a disintegrin domain (ADAM
family), mediate this ectodomain shedding.7 An alternative
pathway that activates many cells operates through limited proteolysis
of cell surface receptors referred to as protease-activated receptors
(PARs).8 Although both pathways are tightly controlled, during bacterial infections the surface proteins and receptors may
become a target for nonhost proteases, which generally escape any
control by host inhibitors. Indeed, growing evidence indicates that
bacterial proteases can modify the host cell surface, and in this
manner, contribute significantly to microbial
pathogenicity.9-17
Periodontitis, the chronic infectious disease in which uncontrolled
proteolytic activity derived from both host and bacteria plays a
significant role in the destruction of tooth-supporting tissues,
including the alveolar bone, is the most prevalent inflammatory disease
in the world. Approximately 15% of the population suffers from its
most severe form and, if untreated, it may result not only in tooth
loss, but also in systemic complications.18-21 The major
pathogens associated with periodontitis are Porphyromonas gingivalis, Bacteroides forsythus, and Actinobacillus
actinomycetemcomitans.22 Among these, P
gingivalis, a gram-negative anaerobic rod, has been identified as
a major etiologic agent in the pathogenesis of adult periodontitis in
humans.22,23 It has also been recognized as a virulence
agent that initiates the progression of periodontitis in primate and
rodent models of periodontal destruction.24
Recently, a number of epidemiologic studies have linked periodontal
disease to heart disease.25-29 For this reason, we have investigated molecular mechanisms that may connect the 2 pathologies, particularly with regard to the effects of proteases from P
gingivalis on cellular components of the coagulation system.
Gram-negative periodontal pathogens often find their way into the
bloodstream (bacteremia) in patients with periodontal disease as a
result of oral hygiene procedures or even chewing.30-33
Furthermore, P gingivalis has not only been found in the
circulation, but has been found to infect atherosclerotic plaques
also.34,35
Proteases produced by P gingivalis have been shown to act as
important pathogenic agents.36 Two types of cysteine
proteases, responsible for the so-called trypsin-like activity of the
bacterium, have been purified37,38: a
lysine-specific protease, 105-kd, termed lys-gingipain (Kgp) and an
arginine-specific protease referred to as arg-gingipain. The latter is
present as 3 variants: 50-kd RgpAcat, 50-kd RgpB, and
95-kd HRgpA. HRgpA is the high molecular mass form of
RgpAcat, formed by RgpAcat noncovalently
complexed with 44-kd binding proteins that have been identified as
hemagglutinins or adhesins.37,39 Curtis and
colleagues40 showed that a protease preparation, termed
protease I, from P gingivalis strain W83 was able to induce
platelet activation, but the biochemical nature of the enzyme and the
mechanism of its action were not elucidated. The questions addressed in
this study are whether the highly characterized proteases RgpB and
HRgpA, which are solely responsible for the hydrolysis of peptide
bonds after arginine residues in P gingivalis, can
elicit a cellular response in platelets that is mediated by interaction
of the enzymes with platelet surface molecules.
Platelets express certain members of the PAR family on their surface
that are activated by cleavage of their N-terminus by a protease, then
couple to G proteins and induce cellular signals. To date, 4 PARs have
been identified: PARs-1, -2, -3, and -4. The new N-terminus that is
formed after receptor cleavage acts as a tethered ligand that binds to
the receptor and leads to its activation. Synthetic peptide agonists
corresponding to the tethered ligand of each receptor are able to
activate the receptor, with the exception of PAR-3, allowing the
cellular responses mediated by the different receptors to be
distinguished and studied by treatment of cells with their respective
agonist peptides. PAR-1 was the first receptor found and is cleaved and
activated by thrombin,41 as are PAR-3 and PAR-4, the 2 thrombin receptors discovered more recently.42-44 Human
platelets express PAR-1,41,45 and its agonist peptide
causes activation and aggregation.41,46,47 PAR-4 is also
expressed in human platelets,43,44,48 although at a lower level than that of PAR-1,48 and a cognate agonist peptide
was found to induce aggregation of human platelets.48 The
possible interactions of RgpB and HRgpA with the PARs expressed on the surface of platelets were investigated in this study and it was conclusively demonstrated that the enzymes are potent agonists for both
PAR-1 and PAR-4, mediating platelet activation and aggregation via
these receptors. This constitutes the first report of bacterial proteases demonstrably acting through these receptors to cause cellular
processes that may underlie reported associations between periodontitis
and cardiovascular disease.
Materials
Tissue culture
Purification of platelets from human blood Platelets were isolated from freshly drawn human blood. Venous blood was anticoagulated by adding 6 volumes of blood to 1 volume of acid-citrate-dextrose (85 mM sodium citrate, 111 mM dextrose, and 71 mM citric acid supplemented with 50 ng/mL prostaglandin I2 [PGI2] and apyrase at 0.67 U/mL). Whole blood was centrifuged at 200g for 20 minutes at room temperature to obtain the supernatant platelet-rich plasma, which was then centrifuged at 730g for 10 minutes at room temperature to sediment the platelets. The platelet pellets were resuspended in 13 mM trisodium citrate, 120 mM NaCl, and 30 mM dextrose, pH 7.0, containing 50 ng/mL PGI2, and washed twice. Platelets were resuspended in extracellular medium [EM] (12 mM NaHCO3, 138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, 10 mM Hepes, 1 mM MgCl2, pH 7.4) or Tyrode buffer (140 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.76 mM Na2HPO4, 5.5 mM dextrose, 5 mM Hepes, 2 mg/mL bovine serum albumin [BSA], pH 7.4), depending on the assay performed.Intracellular calcium measurement Intracellular calcium levels were measured in N1LF, N1LF PAR-1, N1LF PAR-4, and platelets. N1LF, N1LF PAR-1, and N1LF PAR-4 cells were grown to 80% confluence and detached from the culture dishes by treatment with nonenzymatic dissociation solution (Sigma). All cell types were prepared for [Ca++]i measurements as described previously.52 Cells were washed and resuspended at 6 × 106 cells/mL in an EM depending on the cell type. The EM for N1LF, N1LF PAR-1, and N1LF PAR-4 consisted of 121 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 6 mM NaHCO3, 5.5 mM glucose, 25 mM Hepes, 0.1% (wt/vol) BSA, pH 7.3; the EM for platelets was as described above. In all subsequent steps the cells were protected from light.Cells were loaded with 1 µM Fura-2 AM by occasional shaking for 30 minutes at room temperature. After centrifugation at 200g for 5 minutes, they were resuspended in EM and occasionally shaken for 30 minutes at room temperature to allow hydrolysis of the intracellular Fura-2 AM and then centrifuged (200g for 5 minutes). N1LF, N1LF PAR-1, and N1LF PAR-4 cells were resuspended in EM without BSA at 2 × 106 cells/mL for fluorescence measurements and platelets were resuspended in EM containing 1 mM CaCl2. [Ca2+]i was determined using a PerkinElmer LS-50 fluorometer by measuring Fura-2 fluorescence at excitation and emission wavelengths of 340:380 and 510 nm, respectively. Loaded cells were maintained at 37°C in stirred plastic cuvettes throughout the experiment. After a stable baseline was established, the agonist was added to cells and the ratio of fluorescence at the 2 excitation wavelengths was measured, which is proportional to [Ca2+]i. Platelet aggregation studies Platelets were collected from healthy volunteers who had not taken antiplatelet medication for 2 weeks in acid-citrate-dextrose, 6:1 vol/vol, containing 90 mM sodium citrate, 7 mM citric acid, 140 mM dextrose, pH 4.6, supplemented with 70 mM theophylline. Platelet-rich plasma (PRP) was obtained by centrifugation of whole blood at 180g for 15 minutes. The PRP was centrifuged at 2000g for 15 minutes and the platelets washed twice with buffer containing 4.3 mM Na2HPO4, 4.3 mM K2HPO4, 24.3 mM NaH2PO4, 113 mM NaCl, 5.5 mM glucose, 5 mg/mL BSA, 10 mM theophylline, pH 6.5. The final platelet preparation was resuspended in a modified Tyrode buffer, 12 mM NaHCO3, 0.32 mM NaH2PO4, 10 mM Hepes, 137 mM NaCl, 2.7 mM KCl, 0.5 mM MgCl2, and 5.5 mM glucose, pH 7.5. Platelet aggregation was measured using a 4-channel automated platelet analyzer set to 950 rpm at 37°C. Each reaction mixture (400 µL) contained washed platelets (3 × 108/mL), the indicated concentrations of HRgpA, RgpB, or thrombin (Figure 5), no exogenous fibrinogen, and 1 mM CaCl2. The rate and extent of platelet aggregation were monitored by the percentage of light transmission and presented as aggregation tracings.Purification and assay of the bacterial proteases HRgpA and RgpB were purified to homogeneity37,38 and the amount of active enzyme determined by active site titration with F-F-R-chloromethylketone,53 all as described previously. The active site cysteine residue of the gingipains was reduced (activated) for cellular studies with 10 mM cysteine at 37°C for 10 minutes in 0.1 M Tris-HCl, 5 mM CaCl2, pH 7.4. Polymyxin B-S04 (100 µg/mL) was routinely added to inhibit any cellular stimulation by bacterial lipopolysaccharides. Gingipains were inactivated by treatment with 100 µM leupeptin or 2 µM antipain for 10 minutes.
HRgpA and RgpB increase intracellular calcium levels [Ca++]i in platelets To determine whether the gingipains were able to interact with platelet receptors and induce intracellular signals, platelets from 9 donors were isolated and individually tested for a [Ca++]i response to HRgpA, RgpB, and thrombin. As may be seen in Table 1, most donors responded similarly to HRgpA and RgpB in terms of the magnitude of the response to a defined concentration of the bacterial enzymes. HRgpA consistently induced a higher level of [Ca++]i response than the same concentration of thrombin, whereas 10-fold more RgpB consistently gave responses that were considerably lower than thrombin. HRgpA and RgpB induced a dose-dependent increase in [Ca++]i, indicated by the dose responses shown for 2 donors in comparison to thrombin (Figure 1). These data yield an enzyme concentration inducing the half maximal response (EC50) of 2.4 nM and 0.18 nM for thrombin and HRgpA, respectively, in one donor and 0.6 nM and 63 nM for HRgpA and RgpB, respectively, in a second donor. This further indicates that HRgpA is consistently a more potent platelet agonist than thrombin, whereas RgpB is much less potent than the other 2 enzymes. As indicated by the data in Table 1, the magnitude of the [Ca++]i response for thrombin, HRgpA, and RgpB varied to only a moderate extent between donors. HRgpA and RgpB, which had been inactivated by leupeptin, did not induce calcium responses in the platelets (Figure 2A,C), indicating that the [Ca++]i increase induced is due to the proteolytic activity of the enzymes.
The question that was then addressed was whether the increase in
[Ca++]i induced by HRgpA and RgpB activity is
due to cleavage of a PAR on the surface of platelets. Once a PAR is
cleaved by a protease it is unable to be activated a second time by the
same or another protease in a short period of time. Because cleavage of
a PAR desensitizes [Ca++]i responses to
subsequent protease challenges, desensitization of
[Ca++]i responses by HRgpA, RgpB, and
thrombin were examined. When platelets were initially activated with
HRgpA, a secondary response to this enzyme was virtually eliminated
(data not shown). Exposure of platelets to thrombin diminished the
[Ca++]i response to a second challenge with
HRgpA (Figure 3A). Platelets treated with
thrombin or HRgpA still responded to a subsequent challenge with
adenosine diphosphate (ADP) (Figure 2A,B), indicating that the cells
could still respond to an agonist via calcium signaling pathways. The
higher the thrombin concentration added to platelets, the smaller was
the subsequent HRgpA response (Figure 3A). Similarly, treatment of
platelets with HRgpA desensitized the response to a second challenge by
thrombin (Figure 3B) and increasing concentrations of HRgpA
proportionately decreased subsequent thrombin responses (Figure 3B).
Similarly, when platelets were initially exposed to RgpB, a secondary
response to this protease or thrombin was abolished (Figure 2D) and
pretreatment with thrombin desensitized the cells to a subsequent
challenge with RgpB (data not shown). It was shown that the
desensitization of the responses was not due to the enzymes
inactivating each other. This is illustrated, for instance, by the
finding that adding 2 µM antipain (a concentration of inhibitor known
to inhibit HRgpA effectively without affecting thrombin) to the cell
suspension after the initial activation with HRgpA did not affect the
desensitization obtained with thrombin (Figure 2A,B). The addition of
the inhibitor after initially adding inactivated HRgpA also did not
affect subsequent thrombin responses. These findings could be extended
to all systems tested, strongly indicating that the desensitization of
the platelets obtained was purely reflective of prior receptor
cleavage.
These results suggest that HRgpA, RgpB, and thrombin activate common
receptor(s) on platelets. Thrombin activates PAR-1 and PAR-4 on the
surface of human platelets by cleaving after an arginine residue in
their extracellular domain. Because HRgpA and RgpB have high
specificity of cleavage, limited to peptide bonds after arginine
residues, the calcium response observed is probably due to activation
of PAR-1 and PAR-4 by these bacterial enzymes. To investigate whether
the calcium increase elicited by RgpB and HRgpA is mediated by cleavage
of PAR-1, platelets were incubated with rabbit anti-PAR-1
antibody49 or a control rabbit antibody (the latter
serving as a control) for 15 minutes, prior to treatment with RgpB or
HRgpA. Preincubation of platelets with anti-PAR-1 antibody
significantly inhibited thrombin and gingipain-induced calcium
increases, in comparison to pretreatment with a control antibody
(Figure 4A-D).
Once PARs have been activated by their cognate peptide agonist
peptides, they may be rendered desensitized to subsequent exposure to
protease agonists, in much the same way as the desensitization described above for treatment with sequential doses of different proteases.54 Because the agonist peptides for PAR-1
(TRAP-SFRLLN) and PAR-4 (TRAP-4-GYPGQV) are specific for their cognate
receptors in the platelet context, pretreatment with these peptides may desensitize the cells to subsequent treatment with protease agonists targeting the receptors. As may be seen visually in Figure
5, panels A-C, and quantitatively in
Table 2, pretreatment of platelets from 3 donors with either TRAP or TRAP-4, individually, markedly reduced the [Ca++]i response to 1 nM
HRgpA, whereas treatment with a combination of the peptides all but
abolished the response to HRgpA. Pretreatment of the platelets with
HRgpA (Figure 5D) abolished subsequent response to PAR-4-activating
peptide and markedly reduced the response to TRAP. Essentially similar
results were found for thrombin and RgpB (data not shown),
demonstrating that the bacterial proteases most likely induce
[Ca++]i responses in platelets by activating
both PAR-1 and PAR-4 receptors.
HRgpA and RgpB induce platelet aggregation Calcium plays a key role in triggering platelet activation and is the single most important intracellular mediator of cell function. To determine whether the [Ca++]i elevation induced by the gingipains causes platelet activation, aggregation responses of these cells were investigated. Both HRgpA and RgpB induced aggregation of platelets from 6 different donors. The aggregation caused by different concentrations of HRgpA and RgpB in one preparation is shown in Figure 6, panels A and B. A consistent finding was that much higher concentrations of RgpB were required to cause the same degree of aggregation as that induced by HRgpA. To determine whether the platelet aggregation caused by the bacterial proteases was due to their proteolytic activity, the enzymes were inactivated with 100 µM leupeptin. This resulted in total inhibition of the aggregation induced by both gingipains (data not shown), indicating that the cellular effect was due to proteolysis.
Agglutination of red blood cells by P gingivalis and adherence to other bacteria are thought to be mediated at least in part via the proteases of this organism.55,56 To show that the measure of aggregation observed (increase in the light transmittance level) was reflective of true platelet activation and is thus genuine aggregation, rather than an agglutination phenomenon, an inhibitor of platelet activation was used. Preincubation of platelets with 100 ng/mL PGI2 or 10 µM forskolin (inhibitors of platelet activation) at 37°C for 15 minutes completely inhibited the aggregation induced by 0.25 nM HRgpA and 20 nM RgpB (data not shown), verifying that HRgpA and RgpB indeed cause true platelet aggregation. HRgpA and RgpB activate cells stably expressing the PAR-4 receptor To investigate whether HRgpA and RgpB can cleave and activate PAR-4, the calcium response elicited by these 2 enzymes was studied in transfected N1LF cells stably expressing human PAR-4 (N1LF PAR-4) in comparison to nontransfected N1LF cells. Treatment of N1LF PAR-4 cells with 25 nM thrombin (Figure 7A) or 500 µM PAR-4 activating peptide (TRAP-4) (data not shown) elicited an intracellular Ca++ increase, whereas nontransfected N1LF cells did not respond to 500 µM TRAP-4 (data not shown) or 20 nM thrombin (Figure 7B). The calcium responses induced in N1LF PAR-4 cells by 4.5 nM HRgpA and 18 nM RgpB are shown in Figure 7, panels C and E, compared to the lack of response in nontransfected N1LF cells (Figure 7D,F). Concentrations of HRgpA as low as 0.45 nM elicited a Ca++ increase in N1LF PAR-4 cells, whereas concentrations as high as 100 nM of HRgpA did not cause calcium mobilization in nontransfected N1LF cells (data not shown). Thus both HRgpA and RgpB specifically induced an increase in [Ca++]i in N1LF PAR-4 cells, verifying that these enzymes can activate PAR-4. The concentration dependence of such an increase is shown in Figure 8, yielding an enzyme concentration inducing half the maximal response (EC50) of 1.7 nM, 4.6 nM, and 10 nM for receptor activation by HRgpA, RgpB, and thrombin, respectively.
HRgpA and RgpB activate cells stably expressing the human PAR-1 receptor To more definitively determine whether the gingipains can cleave and activate human PAR-1, the calcium response elicited by the 2 enzymes was investigated in transfected N1LF cells stably expressing human PAR-1 (N1LF PAR-1) in comparison to nontransfected N1LF cells. Treatment of N1LF PAR-1 cells with 150 µM TRAP or 20 nM thrombin elicited an intracellular Ca++ increase, whereas nontransfected N1LF cells did not respond to TRAP or to 20 nM thrombin (data not shown). Concentrations of HRgpA or RgpB as low as 2 nM elicited a Ca++ increase in N1LF PAR-1 cells, whereas concentrations of the enzymes as high as 100 nM did not cause calcium mobilization in nontransfected N1LF cells (data not shown). The nontransfected N1LF cells did respond to bradykinin, showing that G-protein-coupled receptor signaling pathways were intact. Thus, HRgpA and RgpB activate the PAR-1 receptor. The concentration dependence of the increase in [Ca++]i in N1LF PAR-1 cells induced by the different enzymes is shown in Figure 9, yielding an enzyme concentration inducing half the maximal response (EC50) of 17 nM, 48 nM, and 0.26 nM for receptor activation by HRgpA, RgpB, and thrombin, respectively.
An emerging theme in the interaction between pathogenic bacteria and the host is the ability of the microbial invader to proteolytically modify the host cell surface proteins, including various receptors. In most cases, bacterial proteases degrade receptors,9,12,13,17 or release soluble ectodomains10,11 leading to desensitization of cellular responses to their physiologic agonist. Such treatment of cells of the immune system may potentially affect antimicrobial defense mechanisms or interfere with the regulation of the inflammatory reaction. These effects can be even more deleterious if receptors such as the PARs are the target of bacterial proteases, because cleavage of these receptors will lead to uncontrolled activation of host cells, which, in the case of platelets, is normally mediated by tightly regulated thrombin cleavage of PAR-1 and PAR-4. However, despite the fact that unchecked platelet activation may have serious pathologic consequences if bacteria possessing such ability find their way into the bloodstream, the interaction between platelets and proteases from pathogenic bacteria has never been systematically investigated. An example of bacteria that are known to escape into the bloodstream on a regular basis are the members of microbial flora forming dental plaque. This ability correlates with the severity of periodontitis when even such simple activities as chewing, flossing, and brushing cause a transient bacteremia.31-33 Fortunately, most of the bacteria are benign oral streptococci, which can cause a serious medical problem (endocarditis), only in subjects with damaged or implanted heart valves.57 In the case of severe periodontitis, however, P gingivalis can also find its way into the circulation and even infect atherosclerotic plaques.34,35 This prompted us to closely investigate the effect of arginine-specific gingipains on platelets. HRgpA and RgpB induce an increase in [Ca++]i in human platelets, which is dependent on their proteolytic activity. Several lines of evidence strongly support the hypothesis that this increase is mediated by activation of PAR-1 and PAR-4. Exposure of human platelets to either of the gingipains desensitized the [Ca++]i response to a second challenge with the same enzyme, a phenomenon that is in agreement with the rapid desensitization that protease-activated receptors undergo after a short period of activation with a protease. Desensitization studies carried out with thrombin showed that when human platelets were activated with this enzyme, a secondary challenge with HRgpA or RgpB was virtually eliminated. Similarly, pretreatment of platelets with the bacterial enzymes desensitized the response to a second challenge with thrombin, suggesting that both enzymes activate the platelet thrombin receptors. The desensitization of the platelets to a subsequent challenge with another protease was not due to inactivation of the calcium signaling pathways, as demonstrated by the ability of the platelets to still respond to a maximal concentration of ADP.58 Antibodies specific for the sequence that occurs immediately amino-terminal to the cleavage site of PAR-1 were able to decrease the [Ca++]i increase caused by HRgpA or RgpB by approximately 50%. This finding supports the proposed mechanism that [Ca++]i mobilization by these proteases is in part mediated by cleavage of PAR-1. Further investigation of the receptors activated by the bacterial proteases used the individual agonist peptides for PAR-1 and PAR-4 to desensitize a subsequent response to the gingipains. For each of the enzymes, it could be shown that prior exposure of the platelets to a combination of the PAR-1 and PAR-4 agonist peptides almost completely abolished the response to the protease. This provides strong evidence that the bacterial proteases induce responses in the platelet by cleaving and activating both PAR-1 and PAR-4. Thrombin activates PAR-1 and PAR-4 expressed on the surface of platelets by cleaving after a specific arginine residue at their respective activation sites. HRgpA and RgpB, which are absolutely specific for hydrolysis at R-X sites, were found to activate both PAR-1 and PAR-4 in transfected cells stably expressing these receptors. HRgpA cleaved the PAR-4 receptor approximately 6 times more efficiently than thrombin, based on evaluation of the enzyme concentration inducing half the maximal response (EC50) in PAR-4-transfected cells, whereas RgpB was approximately 2-fold more efficient. Thrombin was a much more efficient activator of PAR-1, however, activating the receptor 60 times more efficiently than HRgpA and 160 times more efficiently than RgpB. The greater efficiency of thrombin for cleavage of PAR-1 is expected in light of the specific association of the protease with a hirudin-like sequence that binds its fibrinogen-binding exosite.59,60 PAR-4 does not have a hirudin-like domain and this accounts for its less effective cleavage by thrombin compared to PAR-1, as seen in the present study and described elsewhere.43,44 The gingipains would also not be expected to cleave PAR-1 very efficiently in comparison to thrombin because they presumably have no mechanism for additional interactions with the receptor that are analogous to thrombin. HRgpA exhibited higher efficiency in activating both PAR-1 and PAR-4 compared to RgpB. It was previously found that the proteolytic activity of HRgpA was 5 times higher than that of RgpB, despite the fact that both enzymes are equally active on synthetic substrates.38 Similarly, HRgpA has been found to have higher activity than RgpB in activating factor X.61 Both HRgpA and RgpB were more efficient at cleaving PAR-4 compared to PAR-1. Although these enzymes are highly specific for cleavage after arginine residues, less is known about the effect of amino acid residues around the cleavage site on the catalytic potency of HRgpA and RgpB. Investigations using synthetic substrates found HRgpA and RgpB to have similar preferences and no clear preference was observed for particular amino acid residues at the P2 or P3 position (P3-P2-R).38 Elucidation of the crystal structure of RgpB revealed that, with the exception of the entrance hole to the S1 pocket, which is optimized to accommodate arginine side chains, the molecular surface around the active site of the enzyme is relatively flat, with a negative electrostatic potential.62 It is thought that this open binding site and strong binding of the arginine residue enables RgpB to cleave a multitude of R-X bonds in proteins and peptides. HRgpA is comprised of RgpA noncovalently complexed with adhesins. Because the structure of HRgpA has not been elucidated, the role of adhesins in the structure and activity of the enzyme is not known. It may be postulated that the adhesin subunits could affect the interaction of the protease with the surface of the cell by serving as an anchor and stabilizing this interaction. More stable interaction of the enzyme with the cell surface may contribute to more efficient cleavage of protease-activated receptors. Based on the desensitization studies and the ability of HRgpA and RgpB to activate PAR-1 and PAR-4, it can be concluded that the bacterial proteases activate these receptors on the surface of platelets, resulting in calcium mobilization. HRgpA caused a [Ca++]i increase in platelets and aggregation at much lower concentrations than RgpB. This would be expected in view of the fact that HRgpA not only showed much higher efficacy than RgpB in activating PAR-1 and PAR-4 in cells stably expressing these receptors, but was also a more potent activator of PAR-4 than thrombin. In human platelets, PAR-4 messenger RNA (mRNA) has been detected at about 30% of PAR-1 mRNA levels.48 Based on studies using blocking antibodies and peptides that inhibit activation of PAR-1 and PAR-4, it appears that PAR-1 on human platelets responds to low concentrations of thrombin and PAR-4 mediates responses to high concentrations of thrombin.48 HRgpA activates platelets with similar efficiency to thrombin, and this may arise from its more potent cleavage of PAR-4 as seen in the transfected cells. PAR-4 has recently been shown to induce the majority of the calcium signal in platelets,63 thus the more potent activation of PAR-4 by HRgpA could possibly account for the similar level of platelet activation by this enzyme compared to thrombin. HRgpA, by potently activating PAR-4 and at the same time activating the more abundant PAR-1 receptor, may be causing the same overall effect induced by thrombin. Treatment of human platelets with HRgpA or RgpB also resulted in
platelet aggregation, which was dependent on the proteolytic activity
of the enzymes. In platelets treated with either gingipain, the
increase in light transmittance level observed was a true aggregation
phenomenon because pretreatment of platelets with inhibitors of
platelet activation prevented the phenomenon. The aggregation assay was
carried out in the absence of exogenously added fibrinogen. In
thrombin-induced platelet aggregation, fibrinogen is released from the
The data discussed above present compelling evidence that PAR-1 and
PAR-4 on the platelet surface can be activated by R-X-specific bacterial proteases. Taken together with the activation of PAR-2 on
neutrophils14 by these proteases, these data establish a new paradigm in microbial pathogenicity, specifically, that some host
cell functions may be manipulated by bacterial proteases cleaving the
PARs. In the case of P gingivalis, the immediate advantage
of this new pathway for the pathogen may not be clearly apparent.
However, uncontrolled PAR activation will certainly contribute to the
deregulation of the local inflammatory reaction, which can be
beneficial for the microbial community in the pathologic periodontal
pocket. In addition to the PARs, several other cell surface receptors,
including C5a (CD88),13 fMLP-R,12 LPS
receptor (CD14),17
Recently, periodontal diseases have been linked to cardiovascular
illnesses, including heart attack, in a number of epidemiologic studies.20 The consensus viewpoint is that this
correlation is an effect of sustained chronic
inflammation19,65-68 of the periodontium triggered by
continuous release of lipopolysaccharide from gram-negative bacteria in
the subgingival dental plaque. Indeed, significantly increased levels
of proinflammatory cytokines such as interleukin 1 The studies reviewed above provide a conceivable explanation for the emerging correlation between periodontitis and cardiovascular diseases. In this scheme, P gingivalis proteases would have an indirect role as factors aggravating or sustaining chronic inflammation. In light of the accumulated data, however, it is tempting to speculate that gingipains may have a more direct role in cardiovascular complications. Recently, P gingivalis has been immunolocalized in the shoulders of atherosclerotic plaque.35 If these bacterial cells still express gingipains, it is very likely that such proteases will contribute to plaque ulceration and thrombus formation through effective, uncontrolled activation of both PARs and coagulation factors.
Submitted November 2, 2000; accepted February 12, 2001.
Supported by National Health and Medical Research Council (Australia) grant 990199 and Heart Foundation of Australia grant G 99M 0336 (to R.N.P.), grant 6 PO4A 04717 from Committee of Scientific Research (KBN, Poland) (to J.P.) and National Institutes of Health grant DE 09761 (to J.T.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Robert N. Pike, Department of Biochemistry and Molecular Biology, Monash University, PO Box 13D, Clayton, Victoria 3800, Australia; e-mail: rob.pike{at}med.monash.edu.au.
1. Tansey WP. How cells use proteolysis to control their growth. Mol Med. 1999;5:773-782[Medline] [Order article via Infotrieve].
2.
Peschon JJ, Slack JL, Reddy P, et al.
An essential role for ectodomain shedding in mammalian development.
Science.
1998;282:1281-1284 3. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost. 1999;82:298-304[Medline] [Order article via Infotrieve]. 4. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol. 1999;11:614-621[CrossRef][Medline] [Order article via Infotrieve]. 5. Kiessling LL, Gordon EJ. Transforming the cell surface through proteolysis. Chem Biol. 1998;5:R49-R62[CrossRef][Medline] [Order article via Infotrieve]. 6. Mullberg J, Althoff K, Jostock T, Rose-John S. The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw. 2000;11:27-38[Medline] [Order article via Infotrieve]. 7. Schlondorff J, Blobel CP. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J Cell Sci. 1999;112:3603-3617[Abstract].
8.
Coughlin SR.
How the protease thrombin talks to cells.
Proc Natl Acad Sci U S A.
1999;96:11023-11027 9. Ijiri Y, Matsumoto K, Kamata R, et al. Suppression of polymorphonuclear leucocyte chemotaxis by Pseudomonas aeruginosa elastase in vitro: a study of the mechanisms and the correlation with ring abscess in pseudomonal keratitis. Int J Exp Pathol. 1994;75:441-451[Medline] [Order article via Infotrieve]. 10. Vollmer P, Walev I, Rose-John S, Bhakdi S. Novel pathogenic mechanism of microbial metalloproteases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect Immun. 1996;64:3646-3651[Abstract].
11.
Wolf BB, Gibson CA, Kapur V, et al.
Proteolytically active streptococcal pyrogenic exotoxin B cleaves monocytic cell urokinase receptor and releases an active fragment of the receptor from the cell surface.
J Biol Chem.
1994;269:30682-30687 12. Lala A, Amano A, Sojar HT, et al. Porphyromonas gingivalis trypsin-like protease: a possible natural ligand for the neutrophil formyl peptide receptor. Biochem Biophys Res Commun. 1994;199:1489-1496[CrossRef][Medline] [Order article via Infotrieve]. 13. Jagels MA, Travis J, Potempa J, et al. Proteolytic inactivation of the leukocyte C5a receptor by proteases derived from Porphyromonas gingivalis. Infect Immun. 1996;64:1984-1991[Abstract]. 14. Lourbakos A, Chinni C, Thompson P, et al. Cleavage and activation of protease-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis. FEBS Lett. 1998;435:45-48[CrossRef][Medline] [Order article via Infotrieve].
15.
Scragg MA, Cannon SJ, Rangarajan M, et al.
Targeted disruption of fibronectin-integrin interactions in human gingival fibroblasts by the RI protease of Porphyromonas gingivalis W50.
Infect Immun.
1999;67:1837-1843
16.
Katz J, Sambandam V, Wu JH, et al.
Characterization of Porphyromonas gingivalis-induced degradation of epithelial cell junctional complexes.
Infect Immun.
2000;68:1441-1449
17.
Sugawara S, Nemoto E, Tada H, et al.
Proteolysis of human monocyte CD14 by cysteine proteases (gingipains) from Porphyromonas gingivalis leading to lipopolysaccharide hyporesponsiveness.
J Immunol.
2000;165:411-418 18. Offenbacher S, Lieff S, Beck JD. Periodontitis-associated pregnancy complications. Prenat Neonat Med. 1999;3:82-85. 19. Beck J, Garcia R, Heiss G, et al. Periodontal disease and cardiovascular disease. J Periodontol. 1996;67:1123-1137[Medline] [Order article via Infotrieve]. 20. Page RC. The pathobiology of periodontal diseases may affect systemic diseases: inversion of a paradigm. Ann Periodontol. 1998;3:108-120[Medline] [Order article via Infotrieve]. 21. Schenkein H. The pathogenesis of periodontal diseases. J Periodontol. 1999;70:457-470[CrossRef][Medline] [Order article via Infotrieve]. 22. Newman MG. Periodontal diseases: pathogenesis and microbial factors: consensus report of the world workshop in periodontitis. Ann Periodontol. 1996;1:926-932[Medline] [Order article via Infotrieve]. 23. Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. Periodontology. 1994;5:78-111[Medline] [Order article via Infotrieve]. 24. Holt SC, Felton J, Brunsvold M, et al. Implantation of Bacterioides gingivalis in non-human primates initiates progression of periodontitis. Science. 1987;239:55-57. 25. Mattila KJ. Viral and bacterial infections in patients with acute myocardial infarction. J Intern Med. 1989;225:293-296[Medline] [Order article via Infotrieve]. 26. Mattila K, Niemen M, Valtonen V, et al. Association between dental health and acute myocardial infarction. Br Med J. 1989;298:779-782. 27. Mattila K, Valle MS, Niemen M, et al. Dental infections and coronary atherosclerosis. Atherosclerosis. 1993;103:205-211[CrossRef][Medline] [Order article via Infotrieve]. 28. DeStefano F, Anda RF, Kahn HS, et al. Dental disease and risk of coronary heart disease and mortality. Br Med J. 1993;306:688-691. 29. Mattila K, Niemen M, Valtonen VV, et al. Dental infection and the risk of new coronary events: prospective study of patients with documented coronary artery disease. Clin Infect Dis. 1995;20:558-592.
30.
Watanakunakorn C, Pantelakakis J.
Alpha-hemolytic streptococcal bacteremia: a review of 203 episodes during 1980 31. Silver JG, Martin AW, McBride BC. Experiment transient bacteremias in human subjects with varying degrees of plaque accumulation and gingival inflammation. J Clin Periodontol. 1980;4:92-99. 32. Carroll GC, Sebor RJ. Flossing and its relationship to transient bacteremia. J Periodontol. 1980;51:691-692[Medline] [Order article via Infotrieve]. 33. Sconyers JR, Crawford JJ, Moriarty JD. Relationship of bacteremia to toothbrushing in patients with periodontitis. J Am Dent Assoc. 1973;87:616-692[Medline] [Order article via Infotrieve]. 34. Haraszthy VI, Zambon M, Trevisan R, et al. Identification of pathogens in atheromatous plaques [abstract]. J Dent Res. 1998;77:666. 35. Chiu B. Multiple infections in carotid atherosclerotic plaques. Am Heart J. 2000;138:S534-S536. 36. Potempa J, Banbula A, Travis J. Role of bacterial proteases in matrix destruction and modulation of host responses. Periodontology 2000. 2000;24:153-192.
37.
Pike R, McGraw W, Potempa J, Travis J.
Lysine and arginine-specific proteases from Porphyromonas gingivalis: isolation, characterization, and evidence for the existence of complexes with hemagglutinins.
J Biol Chem.
1994;269:406-411
38.
Potempa J, Mikolajczyk-Pawlinska J, Brassell D, et al.
Comparative properties of two cysteine proteases (gingipains R), the products of two related but individual genes of Porphyromonas gingivalis.
J Biol Chem.
1998;273:21648-21657
39.
Pike RN, Potempa J, McGraw W, et al.
Characterization and binding activities of protease-adhesin complexes from Porphyromonas gingivalis.
J Bacteriol.
1996;178:2876-2882 40. Curtis MA, Macey JM, Slaney JM, et al. Platelet activation by protease I W83. FEMS Microbiol Lett. 1993;110:167-173[CrossRef][Medline] [Order article via Infotrieve]. 41. Vu T-K, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068[CrossRef][Medline] [Order article via Infotrieve]. 42. Ishihara H, Conolly AJ, Zeng D, et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature. 1997;386:502-506[CrossRef][Medline] [Order article via Infotrieve]. 43. Kahn ML, Zheng Y-W, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature. 1998;394:690-694[CrossRef][Medline] [Order article via Infotrieve].
44.
Xu W-F, Andersen H, Whitmore TE, et al.
Cloning and characterization of human protease-activated receptor 4.
Proc Natl Acad Sci U S A.
1998;95:6642-6646 45. Hung DT, Vu TK, Wheaton VI, et al. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest. 1992;89:1350-1353.
46.
Vassallo RR Jr, Kieber-Emmons T, Cichowski K, et al.
Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides.
J Biol Chem.
1992;267:6081-6085
47.
Scarborough RM, Naughton MA, Teng W, et al.
Tethered ligand agonist peptides: structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function.
J Biol Chem.
1992;267:13146-13149 48. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879-887[Medline] [Order article via Infotrieve]. 49. Jenkins AL, Bootman MD, Taylor CW, et al. Characterization of the receptor responsible for the thrombin-induced intracellular calcium responses in osteblast-like cells. J Biol Chem. 1993;168:21433-21437. 50. Darrow AL, Fang-Leung WP, Ye RD, et al. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost. 1996;76:860-866[Medline] [Order article via Infotrieve].
51.
Andrade-Gordon P, Maryanoff BE, Derian BE, et al.
Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor.
Proc Natl Acad Sci U S A.
1999;96:12257-12262
52.
Bootman MD, Berridge MJ, Taylor CW.
All or nothing Ca2+ mobilization from the intracellular stores of single histamine-stimulated HeLa cells.
J Physiol.
1992;450:163-178 53. Potempa J, Pike R, Travis J. Titration and mapping of the active site of cysteine proteases from Porphyromonas gingivalis (gingipains) using peptidyl chloromethanes. Biol Chem. 1997;378:223-230. 54. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry. 2000;39:5458-5467[CrossRef][Medline] [Order article via Infotrieve].
55.
Curtis MA, Ramakrishnan M, Slaney JM.
Characterization of the trypsin-like enzymes of Porphyromonas gingivalis W83 using a radiolabelled active site-directed inhibitor.
J Gen Microbiol.
1993;139:949-955
56.
Shi Y, Ratnayake DB, Okamoto K, et al.
Genetic analyses of proteolysis, hemoglobin binding, and hemagglutination of Porphyromonas gingivalis: construction of mutants with a combination of rgpA, rgpB, kgp, and hagA.
J Biol Chem.
1999;274:17955-17960
57.
Herzberg MC.
Platelet-streptococcal interactions in endocarditis.
Crit Rev Oral Biol Med.
1996;7:222-236 58. Vanags DM, Lloyd JV, Rodgers SE, et al. ADP, adrenaline and serotonin stimulate inositol 1,4,5-trisphosphate production in human platelets. Eur J Pharmacol. 1998;358:93-100[CrossRef][Medline] [Order article via Infotrieve]. 59. Vu T-K, Wheaton VI, Hung DT, et al. Domains specifying thrombin-receptor interaction. Nature. 1991;353:674-677[CrossRef][Medline] [Order article via Infotrieve].
60.
Liu L, Vu T-KH, Esmon CT, et al.
The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity.
J Biol Chem.
1991;266:16977-16980
61.
Imamura T, Potempa J, Tanase S, et al.
Activation of blood coagulation factor X by arginine-specific cysteine proteases (gingipain-Rs) from Porphyromonas gingivalis.
J Biol Chem.
1997;272:16062-16067 62. Eichinger A, Beisel H-G, Jacob U, et al. Crystal structure of gingipain R: an Arg-specific bacterial cysteine protease with a caspase-like fold. EMBO J. 1999;18:5453-5462[CrossRef][Medline] [Order article via Infotrieve]. 63. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry. 2000;39:5458-5467. 64. Fox JEB. Regulation of platelet function by the cytoskeleton. In: Authi KS, ed. Mechanisms of Platelet Activation and Control. New York, NY: Plenum Press; 1993:175-185. 65. Loesche WJ. Periodontal disease as a risk factor for heart disease. Compend Contin Educ Dent. 1994;15:976-991. 66. Herzberg MC, Meyer M. Dental plaque, platelets, and cardiovascular disease. J Periodontol. 1998;3:151-160. 67. Joshipura KJ, Douglass CW, Willett WC. Possible explanations for the tooth loss and cardiovascular disease relationship. Ann Periodontol. 1998;3:175-183[Medline] [Order article via Infotrieve]. 68. Lopes-Virella MF, Virella G. Immunological and microbiological factors in the pathogenesis of atherosclerosis. Clin Immunol Immunopathol. 1985;37:377-386[CrossRef][Medline] [Order article via Infotrieve]. 69. Eley BM, Cox SW. Advances in periodontal diagnosis. 5. Potential inflammatory and immune markers. Br Dent J. 1998;184:220-223[CrossRef][Medline] [Order article via Infotrieve].
70.
Lowe GDO, Kweider M, Murray GD, Kinane D, McGowan DA.
Fibrinogen 71. Kweider M, Lowe G, Murray G, et al. Dental disease, fibrinogen and white cell count: links with myocardial infarction? Scot Med J. 1993;38:73-74. 72. Mattila KJ, Rasi V, Niemen M. von Willebrand factor antigen and dental infections. Thromb Res. 1989;56:325-329[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  V. B. Reddy, A. O. Iuga, S. G. Shimada, R. H. LaMotte, and E. A. Lerner Cowhage-Evoked Itch Is Mediated by a Novel Cysteine Protease: A Ligand of Protease-Activated Receptors J. Neurosci., April 23, 2008; 28(17): 4331 - 4335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Uehara, M. Naito, T. Imamura, J. Potempa, J. Travis, K. Nakayama, and H. Takada Dual regulation of interleukin-8 production in human oral epithelial cells upon stimulation with gingipains from Porphyromonas gingivalis J. Med. Microbiol., April 1, 2008; 57(4): 500 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Dommisch, W. O. Chung, M. G. Rohani, D. Williams, M. Rangarajan, M. A. Curtis, and B. A. Dale Protease-Activated Receptor 2 Mediates Human Beta-Defensin 2 and CC Chemokine Ligand 20 mRNA Expression in Response to Proteases Secreted by Porphyromonas gingivalis Infect. Immun., September 1, 2007; 75(9): 4326 - 4333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hirano The Roles of Proteinase-Activated Receptors in the Vascular Physiology and Pathophysiology Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 27 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hashimoto, T. Kadowaki, T. Tsukuba, and K. Yamamoto Selective Proteolysis of Apolipoprotein B-100 by Arg-Gingipain Mediates Atherosclerosis Progression Accelerated by Bacterial Exposure J. Biochem., November 1, 2006; 140(5): 713 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Uehara, K. Muramoto, T. Imamura, K. Nakayama, J. Potempa, J. Travis, S. Sugawara, and H. Takada Arginine-Specific Gingipains from Porphyromonas gingivalis Stimulate Production of Hepatocyte Growth Factor (Scatter Factor) through Protease-Activated Receptors in Human Gingival Fibroblasts in Culture J. Immunol., November 1, 2005; 175(9): 6076 - 6084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Brodala, E. P. Merricks, D. A. Bellinger, D. Damrongsri, S. Offenbacher, J. Beck, P. Madianos, D. Sotres, Y.-L. Chang, G. Koch, et al. Porphyromonas gingivalis Bacteremia Induces Coronary and Aortic Atherosclerosis in Normocholesterolemic and Hypercholesterolemic Pigs Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1446 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tancharoen, K. P. Sarker, T. Imamura, K. K. Biswas, K. Matsushita, S. Tatsuyama, J. Travis, J. Potempa, M. Torii, and I. Maruyama Neuropeptide Release from Dental Pulp Cells by RgpB via Proteinase-Activated Receptor-2 Signaling J. Immunol., May 1, 2005; 174(9): 5796 - 5804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T. A. Luger, and M. D. Hollenberg Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response Endocr. Rev., February 1, 2005; 26(1): 1 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. OSSOVSKAYA and N. W. BUNNETT Protease-Activated Receptors: Contribution to Physiology and Disease Physiol Rev, April 1, 2004; 84(2): 579 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Grau, H. Becher, C. M. Ziegler, C. Lichy, F. Buggle, C. Kaiser, R. Lutz, S. Bultmann, M. Preusch, and C. E. Dorfer Periodontal Disease as a Risk Factor for Ischemic Stroke Stroke, February 1, 2004; 35(2): 496 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Kuramitsu MOLECULAR GENETIC ANALYSIS OF THE VIRULENCE OF ORAL BACTERIAL PATHOGENS: AN HISTORICAL PERSPECTIVE Critical Reviews in Oral Biology & Medicine, September 1, 2003; 14(5): 331 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kamaguchi, T. Ohyama, E. Sakai, R. Nakamura, T. Watanabe, H. Baba, and K. Nakayama Adhesins encoded by the gingipain genes of Porphyromonas gingivalis are responsible for co-aggregation with Prevotella intermedia Microbiology, May 1, 2003; 149(5): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Kerrigan, I. Douglas, A. Wray, J. Heath, M. F. Byrne, D. Fitzgerald, and D. Cox A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation Blood, June 28, 2002; 100(2): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tada, S. Sugawara, E. Nemoto, N. Takahashi, T. Imamura, J. Potempa, J. Travis, H. Shimauchi, and H. Takada Proteolysis of CD14 on Human Gingival Fibroblasts by Arginine-Specific Cysteine Proteinases from Porphyromonas gingivalis Leading to Down-Regulation of Lipopolysaccharide-Induced Interleukin-8 Production Infect. Immun., June 1, 2002; 70(6): 3304 - 3307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. McRedmond, D. J. Fitzgerald ;, R. N. Pike, A. Lourbakos, J. Travis, and J. Potempa A growing set of platelet-activating bacterial proteins Blood, January 1, 2002; 99(1): 387 - 388. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
granules during platelet activation, which then binds to the
glycoprotein IIb-IIIa complex, resulting in aggregation.
1-integrin,
1991.
Scand J Infect Dis.
1993;25:403-408
a "new" cardiovascular risk factor. In:
Ernst E,Koeinig W,Lowe GDO,Meade T, eds.
Fibrinogen and Dental Disease